What type of study is this?

This is a Pre-Registered Trial study (also classified as: Animal Study).

September 10, 2025MoleculesOpen Access

Notoginsenoside R1, a Metabolite from Panax notoginseng, Prevents Paclitaxel-Induced Peripheral Neuropathic Pain in Mice

View Full Paper

Ask AI

Bookmark

NGR1 effectively prevents the development of paclitaxel-induced neuropathic pain in a dose-dependent manner, demonstrating its potential as an analgesic.
The binding affinity of NGR1 to monoacylglycerol lipase was also evaluated, with a binding energy of −7.8 kcal/mol compared to pristimerin's −10.3 kcal/mol.
Using molecular docking and MAGL activity assays, the study explores the reversibility and concentration dependence of NGR1's inhibition of MAGL activity.
Further investigations are necessary to reveal the detailed molecular mechanisms behind NGR1's effects on paclitaxel-induced neuropathic pain.

No takes yet. Share an insight, caveat, or question.

Preclinical study shows notoginsenoside R1 reduces paclitaxel-induced neuropathic pain in mice, indicating MAGL inhibition is a potential target.

Al-Musailem et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Preclinical study shows notoginsenoside R1 reduces paclitaxel-induced neuropathic pain in mice, indicating MAGL inhibition is a potential target.